Disruption of adeB gene has a greater effect on resistance to meropenems than adeA gene in Acinetobacter spp. isolated from University Malaya Medical Centre

Singapore Medical Journal

Volumn 50, Issue 8, 2009, Pages 822-826

  Wong, E W ^a   Mohd Yusof, M Y ^a   Bt Mansor, M ^a   Anbazhagan, D ^a   Ong, S Y ^a   Sekaran, Shamala Devi ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Acinetobacter spp.; AdeABC efflux pump; Antimicrobial resistance; Carbapenam resistance; Multidrug resistance

Indexed keywords

AGAR; AMIKACIN; AMPICILLIN; BACTERIAL ENZYME; BACTERIAL PROTEIN; CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; DRUG METABOLIZING ENZYME; GENTAMICIN; IMIPENEM; MEROPENEM; OXACILLINASE; PROTEIN ADEA; PROTEIN ADEB; PROTEIN ADEC; UNCLASSIFIED DRUG;

ACETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ADEA GENE; ADEB GENE; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG HYDROLYSIS; GENE AMPLIFICATION; GENE DISRUPTION; GENE INACTIVATION; GENE INSERTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN TRANSPORT;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALAYSIA; MEMBRANE TRANSPORT PROTEINS; MODELS, GENETIC; MUTATION; PLASMIDS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; THIENAMYCINS;

EID: 70349280736     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Livermore DM. The threat from the pink corner. Ann Med 2003; 35:226-234
2. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380-391
3. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, et al. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51:565-574 (Pubitemid 36336148)
4. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37:214-220 (Pubitemid 36930352)
5. Bou G, Cerveró G, Domínguez MA, Quereda C, Martínez-Beltrán J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000; 38:3299-3305 (Pubitemid 30693921)
6. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45:3375-3380 (Pubitemid 33107849)
7. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. Biochem Pharmacol 2000; 60:457-470
8. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 2004; 48:3298-3304 (Pubitemid 39129322)
9. Schreckenberger PC, Daneshrar MI, Weyant RS, Hollis DG. Acinetobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of Clinical Microbiology. 8th ed. Washington DC: ASM Press, 2003: 749-779
10. Bouvet PJM, Grimont PAD. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol 1987; 138:569-578
11. Koeleman JGM, Stoof J, Biesmans DJ, Savelkoul PHM, Vandenbroucke-Grauls CMJE. Comparison of amplified ribosomal DNA restriction analysis, random amplified polymorphic DNA analysis, and amplified fragment length polymorphism fingerprinting for identification of Acinetobacter genomic species and typing of Acinetobacter baumannii. J Clin Microbiol 1998; 36:2522-2529 (Pubitemid 28380949)
12. NCCLS. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003. Document no. M24-A.
13. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved - standard 6th ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003. Document no. M7-A6.
14. CLSI. Performance standards for antimicrobial susceptibility tests; approved standard M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, 2005. Document no. M100-S15.
15. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular Class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45:583-588 (Pubitemid 32105297)
16. Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 3198-3202 (Pubitemid 41060561)
17. Hunger M, Schmucker R, Kishan V, Hillen W. Analysis and nucleotide sequence of an origin of DNA replication in Acinetobacter calcoaceticus and its use for Escherichia coli shuttle plasmids. Gene 1990; 87:45-51. (Pubitemid 20139853)
18. Ambler RP, Coulson AF, Frère JM, et al. A standard numbering scheme for the class A beta-lactamases. Biochem J 1991; 276 (Pt 1): 269-270
19. Majiduddin FK, Materon IC, Palzkill TG. Molecular analysis of beta-lactamase structure and function. Int J Med Microbiol 2002; 292:127-137 (Pubitemid 34842183)
20. Ledent P, Raquet X, Joris B, Van Beeumen J, Frère JM. A comparative study of Class D beta-lactamases. Biochem J 1993; 292 (Pt 2):555-562
21. Brown S, Amyes SG. OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother 2006; 57:1-3. (Pubitemid 43057051)
22. Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. J Clin Microbiol 2005; 43:2241-2245 (Pubitemid 40656234)
23. Poirel L, Marqué S, Héritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49:202-208
24. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005; 43:4826-4829 (Pubitemid 41298286)
25. Brown S, Young HK, Amyes SG. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005; 11:15-23. (Pubitemid 40227817)
26. Girlich D, Naas T, Nordmann P. Biochemical characterization of naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48: 2043-2048 (Pubitemid 38691595)
27. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47:247-250
28. Sinha M, Srinivasa H. Mechanisms of resistance to carbapenems in meropenem-resistant Acinetobacter isolates from clinical samples. Indian J Med Microbiol 2007; 25:121-125 (Pubitemid 46986155)